Sign in
4

Changes in Ownership

UNITED THERAPEUTICS Corp Filed Acc 0001673232-25-000016

PRESIDENT AND COO sold 22,500 shares at an average $496.30 ($11,166,722)

  • PRESIDENT AND COO acquired 22,500 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

BENKOWITZ MICHAEL · PRESIDENT AND COO

Table I: Non-derivative

22 lines
Date Transaction Shares Price Value Owned after D/I
2025-12-15 Exercise or conversion : show line 1 in the form 10b5-1 +14,625 $117.76 $1,722,240 14,625 I
2025-12-15 Sale : show line 2 in the form 10b5-1 −260 $491.18 $127,707 14,365 I
2025-12-15 Sale : show line 3 in the form 10b5-1 −1,466 $492.31 $721,733 12,899 I
2025-12-15 Sale : show line 4 in the form 10b5-1 −2,596 $493.25 $1,280,472 10,303 I
2025-12-15 Sale : show line 5 in the form 10b5-1 −1,446 $494.13 $714,518 8,857 I
2025-12-15 Sale : show line 6 in the form 10b5-1 −1,442 $495.29 $714,207 6,076 I
2025-12-15 Sale : show line 7 in the form 10b5-1 −1,339 $496.16 $664,359 7,518 I
2025-12-15 Sale : show line 8 in the form 10b5-1 −520 $497.42 $258,658 5,556 I
Open-market sales · 22,500 sh · avg $496.30 · $11,166,722

Table II: Derivative

2 lines
Date Transaction Shares Owned after D/I
2025-12-15 Exercise or conversion : show line 23 in the form 10b5-1 Stock Options −14,625 141,000 I
2025-12-15 Exercise or conversion : show line 24 in the form 10b5-1 Stock Options −7,875 6,190 I
Loading xslF345X05/primarydocument.xml…